Topical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in White, Black, and Asian Participants [0.03%]
用于治疗甲真菌病的10％Efinaconazole乳膏：对白种人、黑种人和亚洲参与者的三期汇总分析
Shari R Lipner,Aditya K Gupta,Tracey C Vlahovic et al.
Shari R Lipner et al.
Background: Topical efinaconazole 10% solution has demonstrated efficacy and safety in two phase 3 trials of onychomycosis. As clinical data for onychomycosis treatments are limited in patients with skin of color, this po...
Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024 [0.03%]
2018年至2024年FAERS数据库中GLP-1受体激动剂相关皮肤不良事件的分析
Marisa N Fat,Hayden C Johnson,Aaron S Farberg
Marisa N Fat
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for conditions beyond type 2 diabetes, including psoriasis and hidradenitis suppurativa. Despite this, little is known about th...
Evaluation of an Advanced, Multimodal Skin Tone Correcting Serum in Participants With Mild-to-Severe Dyschromia and Hyperpigmentation [0.03%]
评估一种先进的多模式肤色矫正爽肤水对轻至中重度色素不均和色斑参与者的功效
Zoe Diana Draelos,Diane B Nelson
Zoe Diana Draelos
Background: A new multimodal skin tone correcting serum formulated with b.r.y.t.e.r. (brown, red, and yellow tones with enhanced resurfacing) technology (EV-I) targets brown, red, and yellow dyschromia and acts through 5 ...
Regulatory Landscape of Regenerative Dermatology: Current Frameworks and Future [0.03%]
再生性皮肤病学的监管格局：当前框架和未来展望
Rachel L Ziebart,Barbara Hernandez-Rovira,Hema Sundaram et al.
Rachel L Ziebart et al.
Background: Regenerative dermatology is an emerging subspecialty that seeks to restore the structure and function of healthy skin. The United States lacks comprehensive regulatory guidance for regenerative therapies. This...
Racial and Ethnic Disparities in Access to Advanced Therapies for Atopic Dermatitis in the United States [0.03%]
美国湿疹患者接受先进疗法的种族和民族差异
Katrina Abuabara,Christopher G Bunick,Lara Wine Lee et al.
Katrina Abuabara et al.
Background: Atopic dermatitis (AD) disproportionately affects diverse patient populations, and complex factors influence access to treatment among different racial and ethnic groups. ...
Observational Study
Journal of drugs in dermatology : JDD. 2026 Jan 1;25(1):54-60. DOI:10.36849/JDD.9506 2026
Clinical Evaluation of a Thiamidol-Based Regimen With SPF Compared With SPF Alone for Facial Hyperpigmentation [0.03%]
含硫辛酰胺组分与仅含防晒剂组分方案治疗面部色素沉着的临床评价
Susan Taylor,Pearl E Grimes
Susan Taylor
Background: Hyperpigmentation disorders are common skin concerns that negatively impact patient quality of life and self-perception. Hyperpigmentation results from the overproduction of melanin via a multi-step process wi...
Randomized Controlled Trial
Journal of drugs in dermatology : JDD. 2026 Jan 1;25(1):48-53. DOI:10.36849/JDD.9585 2026
A Randomized, Controlled, Split-Face, Double-Blind Study Comparing Topical Malassezin to Hydroquinone 4% for Melasma [0.03%]
5％马拉色菌与4％氢醌治疗黄褐斑的随机对照双盲研究
Pearl E Grimes,Shanaya Dias,Nicole Chizara Oparaugo et al.
Pearl E Grimes et al.
Background: Previous studies have documented the capacity of malassezin to brighten the skin. It represents a novel agent for the treatment of hyperpigmentation. ...
Randomized Controlled Trial
Journal of drugs in dermatology : JDD. 2026 Jan 1;25(1):25-29. DOI:10.36849/JDD.9222 2026
Illuminating LiDAR Use in Dermatologic Surgery: A Pilot Survey Exploring New Dimensions in Procedural Care [0.03%]
关于皮肤外科手术中使用激光雷达的调查：探索护理新维度的一项试点调查研究
Justin W Marson,Yvonne Nong,Manan D Mehta et al.
Justin W Marson et al.
Unveiling Artificial Intelligence's Diagnostic Power and Challenges in Dermatology for Skin of Color: A Review [0.03%]
揭秘人工智能在肤色皮肤病诊断中的潜力与挑战：综述
Ugwumsinachi D Nwaubani,Adaora Ntukogu,Nyla Griffith et al.
Ugwumsinachi D Nwaubani et al.
From Misdiagnosis to Resistance: The Need for Antifungal Stewardship in Dermatology [0.03%]
从误诊到耐药：皮肤科抗真菌管理的必要性
Mina Farah,Nikkia Zarabian,Adam Friedman
Mina Farah